What are the recent financial highlights of KILITCH DRUGS INDIA LTD?

KILITCH DRUGS INDIA LTD recently reported a total revenue of ₹181.91 Cr and a net profit margin of 10.73%. These metrics reflect the company’s consistent financial performance.

What are the key financial metrics of KILITCH DRUGS INDIA LTD?

Key financial metrics include a trailing P/E ratio of 27.557756, forward P/E of 21.830065, book value of ₹117.762, price-to-book ratio of 2.836229, and a market capitalization of ₹5.38 billion.

What does KILITCH DRUGS INDIA LTD do?

Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-inflammatory, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, antifungals, corticosteroids, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, soft gelatin capsules, dry syrup, gripe water, and oral gel, powder, and liquid in the cardiovascular and anti-diabetics areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, and ROIVIT; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, creams, lotions, liquids, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.

Loading...

₹ 0 0.00%

Loading... BSE: Loding... NSE: Kilitch

About

Loading... ^[1]

Website BSE NSE

Market Cap ₹ 0 Cr.
Current Price ₹ 0
High / Low ₹ 0 / 0
Stock P/E
Dividend Yield 0 %
ROE 0 %
EPS 0
P/B Ratio 0
Net Profit Margin 0 %
Debt to Equity 0
ROCE 0 %
Interest Coverage 0 %

Stock News - Kilitch

Latest updates related to Kilitch

Sr No.	Title	Sentiment
1	Kilitch Drugs Reports Strong Sales Growth Amidst Management Efficiency Challenges MarketsMojo	🔄
2	Kilitch Drugs Consolidated December 2024 Net Sales at Rs 56.17 crore, up 76.65% Y-o-Y Moneycontrol	🔄
3	USFDA issues 'warning letter' to Kilitch Healthcare over GMP violation Business Standard	🔄
4	USFDA issues warning letter to Kilitch Healthcare for Navi-Mumbai plant BusinessLine	🔄
5	Kilitch Drugs Limited Q3FY25 PAT registers 222% YoY remarkable growth and Revenue from operations rises up by 77% on consolidated basi IBG NEWS	🔄
6	KILITCH DRUGS Share Price Today Up 9% Equitymaster	🔄
7	FDA lambasts Kilitch for unsanitary manufacturing conditions and issues warning letter to Natco, too FiercePharma	🔄
8	Kilitch Drugs (India) Limited's Subsidiary Won Tender Issued by the Ethiopian Pharmaceutical Supply Service of the Federal Democratic Republic of Ethiopia ANI News	🔄
9	Kilitch Healthcare recalls eye drops amid U.S. FDA investigators finding insanitary conditions The Hindu	🔄
10	Kilitch Healthcare India voluntarily recalls OTC eye drop products Healio	🔄

Peer Comparison

Macro Industry: Loading.. | Sector: Loading.. | Industry: Loading.. | Basic Industry: Loading..

Loading peers table...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Loading data...

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Loading Profit & Loss data...

Compounded Sales Growth
10 Years:
5 Years:
3 Years:
TTM:

Compounded Profit Growth
10 Years:
5 Years:
3 Years:
TTM:

Stock Price CAGR
10 Years:
5 Years:
3 Years:
1 Year:

Return on Equity
10 Years:
5 Years:
3 Years:
Last Year:

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Shareholding Pattern

Numbers in percentages

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Loading...

Loading...

Stock News - Kilitch

Peer Comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Delivery Data

Insider Data

Technical Data

Static Application Security Testing

Documents

Announcements

Annual reports

Credit ratings

Concalls

Explore More Stocks